MarginsXMarginsX
Home › Markets › Health Care › ZTS

Zoetis Inc. (ZTS)

ZTS trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$84.39
+0.68% on the day
Market cap
$34.3B
Large cap
Revenue · 2025
$9.5B
+2.3% on 2024
Net income · 2025
$2.7B
28.2% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1555280/000155528026000011/0001555280-26-000011-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerZTS on NYSE
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2013
SEC CIK0001555280
SEC industry codePharmaceutical Preparations

Financials · 2025

LineValue
Revenue$9.5B
Net income$2.7B
Operating incomeNot in SEC XBRL data
Net margin28.2%
Operating marginOperating income not reported
Revenue growth+2.3%
Cash$2.5B
Total assets$15.5B
P/E (computed)12.8×
P/S (computed)3.6×

Warning signs

Cash runway
Cash-flow positive
$1.3B cash at September 30, 2026
Share count, 1 year
-7.8%
2025-10-31 to 2026-10-30 · -11.5% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
-$1.7M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$1.3B cash; operating cash flow $682.0M a quarter.Report 2026-09-30
Shares outstanding406,316,147 (2026-10-30); 440,693,214 a year earlier; 459,113,691 three years earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, Short Hills, New Jersey, United StatesPCAOB Form AP 2026-03-09
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $886K, sold $2.5M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$2.4B$591.0M$824.0M$1.3B$9.0B$9.5B10-Q 2026-11-05
Q2 2026
2026-06-30
$2.5B$691.0M$655.0M$1.5B$9.0B$9.5B10-Q 2026-08-06
Q1 2026
2026-03-31
$2.3B$601.0M$401.0M$1.9B$9.0B$9.5B10-Q 2026-05-07
Q4 2025
2025-12-31
$2.4B$624.0M$848.0M$2.5B$9.0B$9.5B10-K 2026-02-12
Q3 2025
2025-09-30
$2.4B$721.0M$936.0M$2.1B$7.1B$9.4B10-Q 2026-11-05
Q2 2025
2025-06-30
$2.5B$726.0M$605.0M$1.4B$6.6B$9.4B10-Q 2026-08-06
Q1 2025
2025-03-31
$2.2B$602.0M$515.0M$1.7B$6.6B$9.3B10-Q 2026-05-07
Q4 2024
2024-12-31
$2.3B$581.0M$905.0M$2.0B$6.6B$9.3B10-K 2026-02-12

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32025-08-12
Latest annual report10-K2026-02-12
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-05
Latest proxyDEFA14A2026-04-08

Source: SEC EDGAR submissions feed, 1,004 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+5.6%
1 month+12.8%
3 months+10.5%
Year to date-33.4%
1 year-30.8%
From 52-week high-36.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
GMABGenmab A/S ADS$51.57+0.39%$32.2B
RPRXRoyalty Pharma plc Class A Ordinary Shares$68.53-1.13%$39.3B
ROIVRoivant Sciences Ltd. Common Shares$38.61-2.33%$28.0B
INSMInsmed Incorporated$122.88+1.42%$27.0B
UTHRUnited Therapeutics Corporation$587.88-0.56%$25.0B
ONCBeOne Medicines Ltd.$411.29-1.26%$47.0B
VTRSViatris Inc.$20.74-0.38%$23.8B
TEVATeva Pharmaceutical Industries Limited$42.57-4.34%$49.7B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier